Global Pharma Ophthalmic Market By Type (Retinal Disorders Drugs, Allergic, Inflammatory and Infective Drugs,and others), By Application (Glaucoma, Dry Eye Syndrome, Retinal Diseases, and Other Ophthalmic Indications), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028

Published date: Apr 2022
Report ID: 29073
Number of Pages: 246
Format:

- 1. Pharma Ophthalmic Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Pharma Ophthalmic Market Overview
  - 3.1. Pharma Ophthalmic Market Dynamics
    3.1.1. Drivers
    3.1.2. Opportunities
    3.1.3. Restraints
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Manufacturer Intensity Map
- 4. Global Pharma Ophthalmic Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Pharma Ophthalmic Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. Retinal disorders drugs
  - 4.4. Allergic, inflammatory and infective drugs
  - 4.5. Glaucoma drugs
  - 4.6. Dry eye drugs
  - 4.7. Other ophthalmic drugs
- 5. Global Pharma Ophthalmic Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Pharma Ophthalmic Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Glaucoma
  - 5.4. Dry eye syndrome
  - 5.5. Retinal diseases
  - 5.6. Other ophthalmic indications
- 6. Global Pharma Ophthalmic Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    6.1.1. North America Pharma Ophthalmic Market: Regional Trend Analysis
    6.1.1.1. US
    6.1.1.2. Canada
    6.1.1.3. Mexico
  - 6.2.1. Europe
    6.2.1. Europe Pharma Ophthalmic Market: Regional Trend Analysis
    6.2.1.1. Germany
    6.2.1.2. France
    6.2.1.3. UK
    6.2.1.4. Russia
    6.2.1.5. Italy
    6.2.1.6. Rest of Europe
  - 6.3. Asia-Pacific
    6.3.1. Asia-Pacific Pharma Ophthalmic Market: Regional Trend Analysis
    6.3.1.1. China
    6.3.1.2. Japan
    6.3.1.3. Korea
    6.3.1.4. India
    6.3.1.5. Rest of Asia
  - 6.4. Latin America
    6.4.1. Latin America Pharma Ophthalmic Market: Regional Trend Analysis
    6.4.1.1. Brazil
    6.4.1.2. Argentina
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    6.5.1. Middle East and Africa Pharma Ophthalmic Market: Regional Trend Analysis
    6.5.1.1. GCC
    6.5.1.2. South Africa
    6.5.1.3. Israel
    6.5.1.4. Rest of MEA
- 7. Global Pharma Ophthalmic Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Novartis
    7.3.1. Company Overview
    7.3.2. Financial Highlights
    7.3.3. Product Portfolio
    7.3.4. SWOT Analysis
    7.3.5. Key Strategies and Developments
  - 7.4. Allergan
    7.4.1. Company Overview
    7.4.2. Financial Highlights
    7.4.3. Product Portfolio
    7.4.4. SWOT Analysis
    7.4.5. Key Strategies and Developments
  - 7.5. Valeant
    7.5.1. Company Overview
    7.5.2. Financial Highlights
    7.5.3. Product Portfolio
    7.5.4. SWOT Analysis
    7.5.5. Key Strategies and Developments
  - 7.6. Regeneron
    7.6.1. Company Overview
    7.6.2. Financial Highlights
    7.6.3. Product Portfolio
    7.6.4. SWOT Analysis
    7.6.5. Key Strategies and Developments
  - 7.7. Santen
    7.7.1. Company Overview
    7.7.2. Financial Highlights
    7.7.3. Product Portfolio
    7.7.4. SWOT Analysis
    7.7.5. Key Strategies and Developments
  - 7.8. Bayer
    7.8.1. Company Overview
    7.8.2. Financial Highlights
    7.8.3. Product Portfolio
    7.8.4. SWOT Analysis
    7.8.5. Key Strategies and Developments
  - 7.9. Pfizer
    7.9.1. Company Overview
    7.9.2. Financial Highlights
    7.9.3. Product Portfolio
    7.9.4. SWOT Analysis
    7.9.5. Key Strategies and Developments
  - 7.10. Senju
    7.10.1. Company Overview
    7.10.2. Financial Highlights
    7.10.3. Product Portfolio
    7.10.4. SWOT Analysis
    7.10.5. Key Strategies and Developments
  - 7.11. Akorn
    7.11.1. Company Overview
    7.11.2. Financial Highlights
    7.11.3. Product Portfolio
    7.11.4. SWOT Analysis
    7.11.5. Key Strategies and Developments
  - 7.12. Roche
    7.12.1. Company Overview
    7.12.2. Financial Highlights
    7.12.3. Product Portfolio
    7.12.4. SWOT Analysis
    7.12.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Novartis AG Company Profile
- Allergan
- Valeant
- Regeneron
- Santen
- Bayer AG Company Profile
- Pfizer Inc Company Profile
- Senju
- Akorn
- Roche Holding AG Company Profile
Settings

Related Reports

Our Clients

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $5,999 $2,999 USD / per unit save 50%	Multi User $7,999 $3,499 USD / per unit save 55%	Corporate User $12,999 $4,499 USD / per unit save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 2,999)	Buy Now ($ 3,499)	Buy Now ($ 4,499)